Современные взгляды на патогенез и лечение неоваскулярной глаукомы

Закрыть метаданные

Неоваскулярная глаукома — это разновидность вторичной глаукомы, которая отличается наиболее тяжелым течением и занимает второе место среди причин необратимой слепоты. В обзоре обобщены результаты многочисленных работ, посвященных поиску профилактики и наиболее эффективного лечения данной патологии. Основные направления профилактики формирования неоваскулярной глаукомы — своевременное выявление и устранение ишемических процессов в сетчатке в сочетании с адекватным контролем внутриглазного давления и лечением основного заболевания.

Ключевые слова:

неоваскулярная глаукома

интравитреальное введение анти-VEGF-препаратов

панретинальная лазерная коагуляция сетчатки

неоваскуляризация угла передней камеры

ишемия сетчатки

Авторы:

Федорук Н.А.

ФГБНУ «Научно-исследовательский институт глазных болезней имени М.М. Краснова»

ORCID: 0000-0003-4347-7231

Дата поступления:

01.12.2023

Дата принятия в печать:

15.12.2023

Список литературы:

Barac IR, Pop MD, Gheorghe AI, Taban C. Neovascular secondary glaucoma, ethiology and pathogenesis. Romanian J Ophthalmol. 2015;59(1):24-28.
Palma C, Kim D, Singh A, Singh A. Neovascular glaucoma. In: Glaucoma, Medical Diagnosis and Therapy. Shaarawy TM, Saunders WB, eds. 2nd ed. Elsevier Health Sciences; 2015. P. 425-433.
Yang H, Yu X, Sun X. Neovascular glaucoma: Handling in the future. Taiwan J Ophthalmol. 2018;8(2):60-66. https://doi.org/10.4103/tjo.tjo_39_18
Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, Leite A, Felix JP, Torigoe M, Diniz-Filho A, de Almeida HG. Neovascular glaucoma: a review. Int J Retina Vitr. 2016;2:26. https://doi.org/10.1186/s40942-016-0051-x
Havens SJ, Gulati V. Neovascular Glaucoma. Devel Ophthalmol. 2016;55: 196-204. https://doi.org/10.1159/000431196
Liao N, Li C, Jiang H, Fang A, Zhou S, Wang Q. Neovascular glaucoma: a retrospective review from a tertiary center in China. BMC Ophthalmol. 2016; 16:14. https://doi.org/10.1186/s12886-016-0190-8
Biel NM, Siemann DW. Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett. 2016;380(2):525-533. https://doi.org/10.1016/j.canlet.2014.09.035
Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma — A review. Indian J Ophthalmol. 2021;69(3):525-534. https://doi.org/10.4103/ijo.IJO_1591_20
Филиппов В.М., Петрачков Д.В., Будзинская М.В., Сидамонидзе А.Л. Современные концепции патогенеза диабетической ретинопатии. Вестник офтальмологии. 2021;137(5-2):306-313. https://doi.org/10.17116/oftalma2021137052306
Catrina SB. Impaired hypoxia-inducible factor (HIF) regulation by hyperglycemia. J Mol Med. 2014;92(10):1025-1034. https://doi.org/10.1007/s00109-014-1166-x
Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71-98. https://doi.org/10.2174/157339906775473671
Kovacs K, Marra KV, Yu G, Wagley S, Ma J, Teague GC, et al. Angiogenic and inflammatory vitreous biomarkers associated with increasing levels of retinal ischemia. Invest Ophthalmol Visual Sci. 2015;56(11):6523-6530. https://doi.org/10.1167/iovs.15-16793
Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol. 2016;16(1):150. https://doi.org/10.1186/s12886-016-0327-9
Будзинская М.В., Плюхова А.А. Перспективы антиангиогенной терапии при заболеваниях сетчатки. Офтальмология. 2021;18(3S):638-645. https://doi.org/10.18008/1816-5095-2021-3S-638-645
Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6):502-508. https://doi.org/10.1097/ICU.0b013e3282f0ca54
Kwong TQ, Mohamed M. Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol. 2014;78(4):699-706. https://doi.org/10.1111/bcp.12371
Jeganathan VSE, Wardrop D. A paradigm shift in the management of neovascular glaucoma. New Front Ophthalmol. 2016;2(3):119-124. https://doi.org/10.15761/NFO.1000128
Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, Mizue Y, et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 2002; 25(12):2352. https://doi.org/10.2337/diacare.25.12.2352
Tang Y, Yin H, Wang W, Zhang X, Chu N, Li S, et al. Enhancement of lens extraction-induced MCP-1 upregulation and microglia response in long-term diabetes via c-jun, stat1 and ERK. Life Sci. 2020;261:118360. https://doi.org/10.1016/j.lfs.2020.118360
Feldman-Billard S, Larger É, Massin P. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44(1):4-14. https://doi.org/10.1016/j.diabet.2017.10.014
Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257-1270. https://doi.org/10.1080/14712598.2018.1545836
Sun C, Zhang H, Jiang J, Li Y, Nie C, Gu J, et al. Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy. Int Ophthalmol. 2020;40(2): 467-475. https://doi.org/10.1007/s10792-019-01207-4
Sun C, Zhang H, Tang Y, Chen Y, Li Y, Nie C, et al. Aqueous inflammation and ischemia-related biomarkers in neovascular glaucoma with stable iris neovascularization. Curr Eye Res. 2020;45(12):1504-1513. https://doi.org/10.1080/02713683.2020.1762226
Boss JD, Singh PK, Pandya HK, Tosi J, Kim C, Tewari A, et al. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594-5603. https://doi.org/10.1167/iovs.17-21973
Abcouwer SF. Müller cell-microglia cross talk drives neuroinflammation in diabetic retinopathy. Diabetes. 2017;66(2):261-263. https://doi.org/10.2337/dbi16-0047
Zhang A, Ning L, Han J, Ma Y, Ma Y, Cao W, et al. Neutrophil-To-Lymphocyte ratio as a potential biomarker of neovascular glaucoma. Ocul Immunol Inflammation. 2021;29(2):417-424. https://doi.org/10.1080/09273948.2019.1677916
Ulu SM, Dogan M, Ahsen A, Altug A, Demir K, Acartürk G, et al. Neutrophil-to-lymphocyte ratio as a quick and reliable predictive marker to diagnose the severity of diabetic retinopathy. Diabetes Technol Ther. 2013;15(11): 942-947. https://doi.org/10.1089/dia.2013.0097
Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373-379. https://doi.org/10.2337/db05-1621
Sora D, Takayama K, Taguchi M, Sato T, Sakurai Y, Kanda T, et al. Topical corticosteroid-resolved rubeosis iridis with neovascular glaucoma caused by noninfectious granulomatous uveitis. Case Rep Ophthalmol. 2018;9(1): 243-247. https://doi.org/10.1159/000488137
Ajvazi H, Lutaj P. Clinical impact in the management of neovascular glaucoma. Rom J Ophthalmol. 2015;59(3):154-158.
European Glaucoma society terminology and guidelines for glaucoma, 4th edition — chapter 2: Classification and terminologySupported by the EGS foundation: Part 1: Foreword; introduction; glossary; chapter 2 classification and terminology. Br J Ophthalmol. 2017;101(5):73-127. https://doi.org/10.1136/bjophthalmol-2016-EGSguideline.002
Senthil S, Chary R, Ali MH, Cherukuri JR, Rani PK, Krishnamurthy R, et al. Trabeculectomy for neovascular glaucoma in proliferative diabetic retinopathy, central retinal vein occlusion, and ocular ischemic syndrome: Surgical outcomes and prognostic factors for failure. Indian J Ophthalmol. 2021; 69(11):3341-3348. https://doi.org/10.4103/ijo.IJO_1516_21
Reddy S, Doshi S, Pathengay A, Panchal B. Ocular decompression retinopathy following intracameral bevacizumab injection in a case of proliferative diabetic retinopathy with neovascular glaucoma. Indian J Ophthalmol. 2020; 68(6):1206-1209. https://doi.org/10.4103/ijo.IJO_1401_19
SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015;43(9):803-807. https://doi.org/10.1111/ceo.12559
Zhou M, Xu X, Zhang X, Sun X. Clinical outcomes of ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: A systematic review and meta-analysis. J Glaucoma. 2016;25(7):551-557. https://doi.org/10.1097/IJG.0000000000000241
Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767-1776. https://doi.org/10.1016/S0161-6420(01)00775-8
Dumbraveanu L, Cușnir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Romanian J Ophthalmol. 2021;65(4): 315-329. https://doi.org/10.22336/rjo.2021.66.
Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2015;55: 196-204. https://doi.org/10.1159/000431196
Nakamura Y, Takeda N, Mochizuki M. A case of vasoproliferative retinal tumor complicated by neovascular glaucoma. Retin Cases Brief Rep. 2013;7(4): 338-342. https://doi.org/10.1097/ICB.0b013e3182598eea
Zhou Q, Liang J, Lu H. Intravitreal bevacizumab for ocular metastasis of multiple myeloma. Optom Vis Sci. 2013;90(9):236-240. https://doi.org/10.1097/OPX.0b013e31829caaf7
Hong CH, Arosemena A, Zurakowski D, Ayyala RS. Glaucoma drainage devices: a systematic literature review and current controversies. Surv Ophthalmol. 2005;50(1):48-60. https://doi.org/10.1016/j.survophthal.2004.10.006
Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007;91(12): 1631-1635. https://doi.org/10.1136/bjo.2007.116533
Ghosh S, Singh D, Ruddle JB, Shiu M, Coote MA, Crowston JG. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma. Clin Exp Ophthalmol. 2010;38(4):353-357. https://doi.org/10.1111/j.1442-9071.2010.02285.x
Tan AM, Chockalingam M, Aquino MC, Lim ZI, See JL, Chew PT. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Exp Ophthalmol. 2010;38(3):266-272. https://doi.org/10.1111/j.1442-9071.2010.02238.x
Souissi S, Baudouin C, Labbe A, Hamard P. Micropulse transscleral cyclophotocoagulation using a standard protocol in patients with refractory glaucoma naive of cyclodestruction. Eur J Ophthalmol. 2021;31(1):112-119. https://doi.org/10.1177/1120672119877586
Zaarour K, Abdelmassih Y, Arej N, Cherfan G, Tomey KF, Khoueir Z. Outcomes of micropulse transscleral cyclophotocoagulation in uncontrolled glaucoma patients. J Glaucoma. 2019;28(3):270-275. https://doi.org/10.1097/IJG.0000000000001174
Zemba M, Dumitrescu O-M, Vaida F, Dimirache E-A, Pistolea I, Stamate AC, et al. Micropulse vs. continuous wave transscleral cyclophotocoagulation in neovascular glaucoma. Exp Ther Med. 2022;23(4):278. https://doi.org/10.3892/etm.2022.11207
Vasudev D, Blair MP, Galasso J, Kapur R, Vajaranant T. Intravitreal bevacizumab for neovascular glaucoma. J Ocul Pharmacol Ther. 2009;25(5): 453-458. https://doi.org/10.1089/jop.2009.0036
Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol. 2009;3: 685-688. https://doi.org/10.2147/opth.s7698
Putera I, Suryono AN, Artini W. Challenging Management of Neovascular Glaucoma to Achieve the Best Visual Outcome. Case Rep Ophthalmol. 2020; 11(1):85-91. https://doi.org/10.1159/000506041
Chen HJ, Wang CG, Dou HL, Feng XF, Xu YM, Ma ZZ. Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy. Ann Palliat Med. 2020;9(1):82-89. https://doi.org/10.21037/apm.2020.01.10
Shen X, Chen Y, Wang Y, Yang L, Zhong Y. Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy. J Ophthalmol. 2016;4108490. https://doi.org/10.1155/2016/4108490
Sun JT, Liang HJ, An M, Wang DB. Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. Int J Ophthalmol. 2017;10(3):400-405. https://doi.org/10.18240/IJO.2017.03.12
Lyssek-Boroń A, Wylęgała A, Dobrowolski D, Kowalczyk E, Polanowska K, Wylęgała E. Evaluation of EX-PRESS glaucoma implant in elderly diabetic patients after 23G vitrectomy. Clin Intervent Aging. 2017;12:653-658. https://doi.org/10.2147/CIA.S128618
Петрачков Д.В., Коробов Е.Н., Аржуханов Д.Д. Роль витрэктомии в лечении диабетической ретинопатии. Офтальмология. 2021;18(3S): 718-726. https://doi.org/10.18008/1816-5095-2021-3S-718-726

Закрыть метаданные